Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"U.S. Army DEVCOM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iNtRON Signs Bacteriophage Development Project with U.S. Army DEVCOM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$CHECK CHECK","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Exclusive License and Option Agreement for Potential First-In-Class Clinical-Stage Antibacterial Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iNtRON, Executes Evaluation License and Option Agreement for SAL200","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Exclusive License and Option Agreement for Potential First-in-class Clinical-Stage Antibacterial Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iNtRON, Development of PHAGERIA\u00ae Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by iNtRON Biotechnology

    Menu

    iNtRON Biotechnology

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              iNtRON Biotechnology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform Technology

              Details:

              P18-BE3CRC is a drug candidate developed using the Phageria platform technology for bacteriophage-based drugs. It is being evaluated in preclinical trials for the treatment of colorectal cancer.

              Lead Product(s): P18-BE3CRC

              Therapeutic Area: Oncology Product Name: P18-BE3CRC

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iNtRON Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea Announces Exclusive License and Option Agreement for Potential First-In-Class Clinical-Stage Antibacterial Agent

              Details:

              Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license LSVT-1701 (tonabacase) for further clinical development and commercialization.

              Lead Product(s): Tonabacase

              Therapeutic Area: Infections and Infectious Diseases Product Name: LSVT-1701

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Basilea Pharmaceutica

              Deal Size: $CHECK CHECK Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iNtRON Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea Announces Exclusive License and Option Agreement for Potential First-in-class Clinical-Stage Antibacterial Agent

              Details:

              Under the agreement, Basilea will investigate SAL200 (tonabacase), a potential first-in-class clinical-stage antibacterial of the endolysin class, against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.

              Lead Product(s): Tonabacase

              Therapeutic Area: Infections and Infectious Diseases Product Name: SAL200

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Basilea Pharmaceutica

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iNtRON Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iNtRON, Executes Evaluation License and Option Agreement for SAL200

              Details:

              Under the agreement, iNtRON grants Basilea exclusive right for preclinical evaluation of the antibacterial bio-drug N-Rephasin SAL200 (tonabacase), a novel endolysin-based anti-staphylococcal drug formulated for injection.

              Lead Product(s): Tonabacase

              Therapeutic Area: Infections and Infectious Diseases Product Name: N-Rephasin SAL200

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Basilea Pharmaceutica

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iNtRON Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iNtRON Signs Bacteriophage Development Project with U.S. Army DEVCOM

              Details:

              The agreement aims to develop bacteriophages targeting strains causing urinary tract infections for combating Uropathogenic Escherichia coli (UPEC) infections.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: U.S. Army DEVCOM

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iNtRON Biotechnology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates

              Details:

              CDL200 is a novel endolysin-based anti- Clostridioides difficile causes an infection of colon, showed potent and rapid activity against 100% clinical isolates from multi-nation and has no disturbance of normal flora in human's gut.

              Lead Product(s): CDL200

              Therapeutic Area: Infections and Infectious Diseases Product Name: CDL200

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY